Egypt’s Health ministry and GlaxoSmithKline plc (GSK), a British multinational pharmaceutical and biotechnology company, have signed an agreement to improve health in the Arab country.
The agreement encompasses several key areas, including increased public awareness campaigns and specialized training for professionals in the field of child and elderly immunizations, the ministry’s official spokesman Hossam Abdel-Ghaffar told the media.
“The two partners will collaborate on joint projects to achieve multiple objectives, including raising awareness about chronic obstructive pulmonary disease and combating antimicrobial resistance,” Abdel-Ghaffar added.
Under the agreement, GSK “will provide training for healthcare experts on vital topics such as smoking cessation, disease prevention, and accurate patient diagnosis.”
GlaxoSmithKline is a multinational healthcare and pharmaceutical company, actively involved in research, development, and manufacture of pharmaceutical medications, vaccines, and consumer healthcare products. GSK is the 10th largest pharmaceutical company in the world and number 294 on the 2022 Fortune Global 500.